Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
April 7, 2023


The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Reference
https://lnkd.in/dD5Qg4n8Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.




